This is a working overview of research peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
== Causes == The cause of biliary atresia in most infants is not fully understood and it is well possible that a number of factors may play a role, but especially maternal rotavirus infection during pregnancy and subsequent transmission of the virus to the child resulting in infection of the biliary epithelium and subsequent occluding fibrosis may be important in this respect. Some cases may relate to infection with other viruses such as SARS-CoV-2, hepatotropic virus reovirus 3, or congenital cytomegalovirus. In addition, autoimmune processes may contribute to pathogenesis in some cases as well. However, with regard to these alternative causation the experimental evidence remains rather weak.
=== Reaction Steps === During amino acid activation, each amino acid (aa) is attached to its corresponding tRNA molecule. The coupling reaction is catalyzed by a group of enzymes called aminoacyl-tRNA synthetases (named after the reaction product aminoacyl-tRNA or aa-tRNA). The coupling reaction proceeds in two steps: First, the carboxyl group of the backbone of the amino acid is covalently linked to the α-phosphate of the ATP molecule, releasing inorganic pyrophosphate (PPi) and creating a 5’ aminoacyl adenylate intermediate (aa-AMP). 1. aa + ATP ⟶ aa-AMP + PPi Second, the aminoacyl adenylate intermediate undergoes nucleophilic attack, attaching an aminoacyl group to the tRNA at the 3’-OH, and freeing an AMP molecule. 2. aa-AMP + tRNA ⟶ aa-tRNA + AMP There are two classes of aminoacyl t-RNA synthetases: class I and class II. Class I enzymes catalyze transfer of the aminoacyl group to the 2’-OH of the tRNA molecule, and a subsequent transesterification reaction moves the aminoacyl group to the 3’-OH of the tRNA. Class II enzymes catalyze transfer of the aminoacyl group directly to the 3’-OH of the tRNA in a single step. The resulting aminoacyl-tRNA molecule is identical regardless of the enzyme class. The net reaction is: aa + ATP + tRNA ⟶ aa-tRNA + AMP + PPi The amino acid is coupled to the terminal nucleotide at the 3’-end of the tRNA (the A in the sequence CCA) via an ester bond. The formation of the ester bond conserves a considerable part of the energy from the activation reaction.
== Sponsored events == Chick-fil-A Classic The Chick-fil-A Classic is a high school basketball tournament held in Columbia, South Carolina, featuring nationally ranked players and teams. The tournament is co-sponsored by the Greater Columbia Educational Advancement Foundation (GCEAF), which provides scholarships to high school seniors in the greater Columbia area. Chick-fil-A Peach Bowl The Chick-fil-A Peach Bowl, first known as the Peach Bowl until 2006 and renamed Chick-fil-A Peach Bowl in 2014, is a college football bowl game played each year in Atlanta, Georgia. Chick-fil-A Kickoff Game The Chick-fil-A Kickoff Game is an annual early-season college football game played at the Mercedes-Benz Stadium in Atlanta, Georgia; before 2017, it was played at the Georgia Dome. It features two highly ranked teams, one of which has always been from the Southeastern Conference. The event was expanded to two games in the 2012 season and again in the 2014 season. It was also two games in 2017. On July 12, 2023, Georgia-based insurance company Aflac, became the new sponsor of the game.
Hoyle, F.; Wickramasinghe, N.C. (1979). "Biochemical chromophores and the interstellar extinction at ultraviolet wavelengths". Astrophysics and Space Science. 65 (1): 241–244. Bibcode:1979Ap&SS..65..241H. doi:10.1007/BF00643503. S2CID 120184918. Hoyle, F.; Wickramasinghe, N.C.; Al-Mufti, S.; et al. (1982). "Infrared spectroscopy over the 2.9-3.9 μm waveband in biochemistry and astronomy". Astrophysics and Space Science. 83 (1–3): 405–409. Bibcode:1999Ap&SS.268..161H. doi:10.1023/A:1002417307802. Hoyle, F.; Wickramasinghe, N.C.; Al-Mufti, S. (1982). "Organo-siliceous biomolecules and the infrared spectrum of the Trapezium nebula". Astrophysics and Space Science. 86 (1): 63–69. Bibcode:1982Ap&SS..86...63H. doi:10.1007/BF00651830. S2CID 120249547. Hoyle, F.; Wickramasinghe, N.C. (1983). "Bacterial life in space". Nature. 306 (5942): 420. Bibcode:1983Natur.306..420H. doi:10.1038/306420a0. PMID 6646221. Hoyle, F. and Wickramasinghe, N.C., 1986. The case for life as a cosmic phenomenon, Nature 322, 509-511 Hoyle, F. and Wickramasinghe, N.C., 1990. Influenza – evidence against contagion, Journal of the Royal Society of Medicine 83. 258-261 Napier, W.M.; Wickramasinghe, J.T; Wickramasinghe, N.C. (2007). "The origin of life in comets". International Journal of Astrobiology. 6 (4): 321–323. Bibcode:2007IJAsB...6..321N. doi:10.1017/S1473550407003941. S2CID 121008660. Rauf, K.; Wickramasinghe, C. (2010). "Evidence for biodegradation products in the interstellar medium". International Journal of Astrobiology. 9 (1): 29–34. Bibcode:2010IJAsB...9...29R. doi:10.1017/S1473550409990334.
Sources: en.wikipedia.org
Opioid receptors are a group of inhibitory G protein-coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. Even though at the cellular level they are inhibitory, their activation is not always inhibitory: for example, activation of mu-opioid receptors activates (not inhibits) dopamine release, and activation of kappa-opioid receptors can lead to noradrenaline release, due to the location of these receptors on suppressor-cells releasing these neurotransmitters . The opioid receptors are ~40% identical to somatostatin receptors (SSTRs). Opioid receptors are distributed widely in the brain, in the spinal cord, on peripheral neurons, and digestive tract.
== Measurement techniques == Standard organic geochemical methods are employed to prepare samples of dinosterol for analysis. Collected algae samples can be centrifuged and then lyophilized. A Bligh and Dyer extraction can then be performed to isolate the major lipid classes. Lipid samples are often derivatized with bis(trimethylsilyl)trifluoroacetamide (BSTFA) for gas chromatography-mass spectrometry (GC-MS) analysis.
cyclin family proteins: Cyclin D, Cyclin E transcriptional regulators: Myc, E2f1, p130 cyclin-dependent kinase inhibitors (CKIs): p27Kip1, p21, Wee1 centriole proteins: Cep250, Ninein There are approximately seventy human FBPs, several of which are involved in cell cycle control as a component of SCF complexes. Skp2 is an FBP that binds CKIs such as p27Kip1 and p21. Skp2 binds p27Kip1 only when two conditions are met: p27Kip1 is phosphorylated by E/A/CKD2 and bound to Cks1. As a consequence of binding Skp2, p27Kip1 is ubiquitinated and targeted for degradation in late G1 and early S. SCF-Skp2 also targets p130 for degradation in a phosphorylation dependent manner. Beta-transducin repeat-containing protein (βTRCP) is an FBP that targets emi1—an APC/C-Cdh1 inhibitor—and wee1 for degradation during early mitosis. βTRCP recognizes these substrates after they are phosphorylated by Polo-like kinase 1 or Cyclin B-CDK1. Fbw7, which is the human homolog of cdc4 in yeast, is an FBP that targets Cyclin E, Myc, Notch and c-Jun for degradation. Fbw7 is stable throughout the cell cycle and is localized to the nucleus due to the presence of a nuclear localization sequence (NLS). SCF-Fbw7 targets Sic1—when at least six out of nine possible sites are phosphorylated—and Swi5 for degradation. Since Sic1 normally prevents premature entry into S-phase by inhibiting Cyclin B-CDK1, targeting Sic1 for degradation promotes S-phase entry.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.